Inactive Instrument

News Lannett Company, Inc.

Stocks

LCI

US5160122009

Pharmaceuticals

All News

06-28	Aurobindo Pharma USA, Inc. completed the acquisition of Lannett Company, Inc.	CI
06-24	Aurobindo Pharma Limited and Lannett Company Inc Federal Trade Commission Proposes Settlement Requiring Divestiture of Generic Drug Products	CI
05-29	Lannett Company, Inc Recalls Primidone Tablets USP 250mg Due To Cross Contamination	CI
05-19	FDA Approves Lannett, Lanexa Biologics, And Sunshine Lake Pharma’s Interchangeable Insulin Glargine Biosimilar	AQ
29/07/25	Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire Lannett Company, Inc. in a transaction valued at $250 million.	CI
16/06/23	Lannett Company, Inc. Emerges as a Private Company with New Board of Directors	CI
16/06/23	Lannett Company, Inc. Emerged from Bankruptcy	CI
08/06/23	First Amended Prepackaged Joint Plan of Reorganization and Disclosure Statement Approved for Lannett Company, Inc.	CI
05/06/23	First Amended Prepackaged Joint Reorganization Plan Filed by Lannett Company, Inc.	CI
15/05/23	Lannett Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
04/05/23	Motion for Joint Administration Approved for Lannett Company, Inc.	CI
04/05/23	Combined Hearing for Disclosure Statement and Plan Approved for Lannett Company, Inc.	CI
03/05/23	Motion for Joint Administration Filed by Lannett Company, Inc.	CI
03/05/23	LANNETT COMPANY, INC. FILES PREPACKAGED CHAPTER 11 CASES TO SIGNIFICANTLY STRENGTHEN FINANCIAL POSITION	PR
02/05/23	Prepackaged Joint Reorganization Plan and Disclosure Statement Filed by Lannett Company, Inc.	CI
02/05/23	Lannett Company, Inc. Filed for Bankruptcy	CI
01/05/23	Lannett Company, Inc. Enters Into Restructuring Support Agreement	PR
25/04/23	Lannett Company, Inc.(OTCPK:LCIN) dropped from S&P TMI Index	CI
20/04/23	NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS	PR
14/04/23	LANNETT CO INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
14/04/23	John Kozlowski Leaves Lannett Company, Inc. as Principal Accounting Officer, Effective May 16, 2023	CI
14/04/23	John Kozlowski Leaves Lannett Company, Inc. as Chief Financial Officer, Effective May 16, 2023	CI
04/04/23	LANNETT CO INC : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/04/23	Lannett Company, Inc. Announces Positive Results from Pivotal Clinical Insulin Trial	CI
04/04/23	LANNETT SHARES UPDATE	PR